| Value | ₹17.25 Cr |
|---|
BSE filing, NSE: RUBICON. Summary written from the filing by ALFA Finder's alert engine.
Rubicon Research Ltd: key numbers
- Share price
- ₹1,667.40
- Market cap
- ₹27,601 Cr
- Revenue (annual)
- ₹1,754 Cr
- Net profit (annual)
- ₹246.7 Cr
- P/E (TTM)
- 95.8×Sector 47.2×
- Promoter holding
- 51.25%-8.51% QoQ
- FII holding
- 9.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Rubicon Research Ltd
All →Rubicon Research Business Update
Rubicon Research disclosed a USFDA inspection of its Ambernath facility, which issued five procedural Form 483 observations. No monetary penalty or amount is involved.
Rubicon Research Board Meeting Date
Rubicon Research scheduled its Board for November 5, 2026, to consider unaudited financial results for the half year ended September 2026. Trading window closed since October 1.
Rubicon Research Other Announcement
Rubicon Research Ltd filed its quarterly shareholding pattern for the quarter ended September 30, 2026, pursuant to Regulation 31(1)(b) of the LODR Regulations.
Rubicon Research Business Update
Rubicon Research reported the conclusion of a US FDA inspection at its Satara facility. The audit yielded one procedural observation unrelated to data integrity.
Rubicon Research Employee Stock Options
Rubicon Research allotted 7,200 equity shares under its Employee Stock Option Scheme 2022. This issuance marginally increases the company's total paid-up share capital.
Rubicon Research Capital Structure Change
Employee Girish Subramaniam Iyer sold 6,796 shares in the open market across four transactions for a total consideration of ₹1.23 Crore.
- Value
- ₹1.23 Cr
Other legal & regulatory announcements
All →Nephrocare Health Services Legal & Regulatory
Nephrocare's Uzbek subsidiary won a court ruling invalidating a ₹14.79 crore tax demand. The tax department must reconsider the audit, and the decision remains appealable.
- Value
- ₹14.79 Cr
Supriya Lifescience Legal & Regulatory
Supriya Lifescience disclosed that its General Manager, Sales & Marketing, was granted bail in an NDPS Act case. The company says the order has no material impact.
Muthoot Finance Legal & Regulatory
Muthoot Finance disclosed a GST Department search and seizure at its Registered Office, conducted October 29-30, 2026. The company states business operations remained unaffected and it is cooperating fully.
Praveg Legal & Regulatory
Praveg received a SEBI penalty order of ₹2 lakh over amalgamation-related non-compliance. The penalty is payable within 45 days.
- Value
- ₹0.02 Cr
Tube Investments of India Legal & Regulatory
Tube Investments received a Punjab Pollution Control Board order imposing ₹39 lakh environmental compensation for partial non-compliance with its Consent to Operate. The company says there is no material impact on its operations or finances.
- Value
- ₹0.39 Cr
Mitsu Chem Plast Legal & Regulatory
Mitsu Chem Plast clarified a late disclosure of its auditor's conversion into an LLP. No auditor change occurred, and the company acknowledged the lapse.